{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007317","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.060207+00:00","generated_at":"2026-06-18T05:15:20.011336+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enanta reports <5% cash held at SVB; no material impact on runway","bullets":["Less than ~5% of Enanta's cash and marketable securities were in Silicon Valley Bank operating accounts.","Remaining investments held in custody accounts at an independent institution.","No material impact on projected cash runway or operations from SVB exposure.","Disclosure made on March 10, 2023 amid SVB liquidity crisis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007317","json":"https://secwatch.observer/filing/0000950170-23-007317.json","markdown":"https://secwatch.observer/filing/0000950170-23-007317.md","text":"https://secwatch.observer/filing/0000950170-23-007317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023007317/0000950170-23-007317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023007317/enta-20230310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:15:20.011336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}